BlinkLab Limited, a company based in Perth, Australia, has received a refund of $822,205 through the Australian Government’s Research and Development (R&D) Tax Incentive program. This funding pertains to eligible R&D expenses incurred during a pilot study in the United States and various clinical research initiatives conducted in Australia.
The refund is particularly significant as it includes collaborative research associated with the MAGNET study at Monash University. These efforts are focused on advancing the development, validation, and clinical investigation of BlinkLab’s smartphone-based neurobehavioural assessment technology aimed at diagnosing autism.
The financial boost from the R&D Tax Incentive is expected to enhance BlinkLab’s capacity to continue its research and development activities. The company plans to allocate these funds towards ongoing clinical studies and the broader development of its products and regulatory initiatives. This financial flexibility comes at a crucial time as BlinkLab prepares to initiate its primary study with the U.S. Food and Drug Administration (FDA) and begin enrolling participants.
About BlinkLab Limited
Founded by neuroscientists from Princeton University, BlinkLab has developed an innovative smartphone-based diagnostic platform targeting autism and Attention Deficit Hyperactivity Disorder (ADHD). The company’s flagship product serves as a diagnostic aid for clinicians, utilizing smartphones, artificial intelligence, and machine learning to facilitate early and accurate detection of autism. This technology is designed to enable timely interventions during critical periods of brain development, which can significantly improve outcomes for affected individuals.
BlinkLab is guided by a seasoned management team and Board with extensive expertise in digital healthcare, computer vision, AI, and machine learning. Additionally, the company is bolstered by a Scientific Advisory Board comprising leading experts in autism and brain development, ensuring that its research remains at the forefront of the field.
The recent funding announcement demonstrates BlinkLab’s commitment to advancing its pioneering technology in autism diagnosis and highlights the ongoing support from the Australian Government for innovative research initiatives. As the company moves forward, it aims to make a meaningful impact in the realm of neurodevelopmental disorders, ultimately contributing to improved diagnostic processes and early intervention strategies.
